Diagnosis of the Multiepitope Protein rMELEISH3 for Canine Visceral Leishmaniasis

Canine visceral leishmaniasis (CVL) is a major zoonosis that poses a growing challenge to public health services, as successful disease management requires sensitive, specific, and rapid diagnostic methods capable of identifying infected animals even at a subclinical level. The objective of this stu...

Full description

Saved in:
Bibliographic Details
Main Authors: Rita Alaide Leandro Rodrigues, Mariana Teixeira de Faria, Isadora Braga Gandra, Juliana Martins Machado, Ana Alice Maia Gonçalves, Daniel Ferreira Lair, Diana Souza de Oliveira, Lucilene Aparecida Resende, Maykelin Fuentes Zaldívar, Ronaldo Alves Pinto Nagem, Rodolfo Cordeiro Giunchetti, Alexsandro Sobreira Galdino, Eduardo Sergio da Silva
Format: Article
Language:English
Published: MDPI AG 2025-08-01
Series:Applied Sciences
Subjects:
Online Access:https://www.mdpi.com/2076-3417/15/15/8683
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Canine visceral leishmaniasis (CVL) is a major zoonosis that poses a growing challenge to public health services, as successful disease management requires sensitive, specific, and rapid diagnostic methods capable of identifying infected animals even at a subclinical level. The objective of this study was to evaluate the performance of the recombinant chimeric protein rMELEISH3 as an antigen in ELISA assays for the robust diagnosis of CVL. The protein was expressed in a bacterial system, purified by affinity chromatography, and evaluated through a series of serological assays using serum samples from dogs infected with <i>Leishmania infantum.</i> ROC curve analysis revealed a diagnostic sensitivity of 96.4%, a specificity of 100%, and an area under the curve of 0.996, indicating excellent discriminatory power. Furthermore, rMELEISH3 was recognized by antibodies present in the serum of dogs with low parasite loads, reinforcing the diagnostic potential of the assay in asymptomatic cases. It is concluded that the use of the recombinant antigen rMELEISH3 could significantly contribute to the improvement of CVL surveillance and control programs in endemic areas of Brazil and other countries, by offering a safe, reproducible and effective alternative to the methods currently recommended for the serological diagnosis of the disease.
ISSN:2076-3417